Selpercatinib (Retevmo) 80mg: How Selective RET Kinase Binding Differs From Multi-Kinase TKIs

Overview

The defining feature of selpercatinib is architectural: the molecule was designed around the RET kinase pocket rather than adapted from a broader kinase scaffold. That design choice is what separates LOXO-292 from earlier agents that reached RET only as a secondary activity. Supplied by Eli Lilly under the brand Retevmo in 80mg tablets, 60 per pack, this presentation supports the higher maintenance dose used in adult oncology practice.

How It Works

RET encodes a receptor tyrosine kinase that becomes constitutively active when a fusion partner replaces its normal regulatory domain, or when a point mutation locks the kinase in an open conformation. Selpercatinib occupies the ATP-binding site of that altered kinase with high affinity while sparing VEGFR2 and other structurally related receptors. The practical consequence is pharmacological rather than theoretical: because VEGFR2 is largely untouched, the hypertension and wound-healing signals that dominate multi-kinase dosing are far less prominent, allowing sustained exposure at the intended dose intensity. Activity is retained against several gatekeeper substitutions that blunt older compounds.

Indications

Registered use covers RET fusion-positive non-small cell lung cancer, RET-mutant medullary thyroid carcinoma, and RET fusion-positive thyroid cancer that no longer responds to radioactive iodine. The product listing also references pancreatic tumours, reflecting the tissue-agnostic logic that follows from targeting a driver alteration wherever it is detected. Eligibility always begins with a validated NGS or FISH result confirming the RET alteration.

Dosage & Administration

Adults weighing 50kg or more typically take 160mg twice daily, achieved with two 80mg tablets per dose; those under 50kg take 120mg twice daily. Tablets are swallowed whole with or without food, roughly twelve hours apart. Hepatic transaminases, blood pressure and QT interval are monitored, with stepwise dose reduction preferred over interruption.

Storage & Sourcing

Store below 30°C in the original blister, protected from moisture. Each 60-tablet pack covers under a week at full dose, so distributors should model consumption against that turnover rather than per-pack count. Confirm batch number, manufacturing date and remaining shelf life on the certificate of analysis before accepting a consignment.

FAQ

Q: Why does selectivity for RET matter when a multi-kinase inhibitor also hits the target? Off-target VEGFR2 blockade forces dose reductions that lower RET coverage. A selective binder keeps effective concentration on the driver kinase without that trade-off.

Q: Does selpercatinib remain active after resistance to a multi-kinase inhibitor? Patients previously exposed to non-selective agents can still respond, because prior treatment rarely selects for RET-specific resistance substitutions.

Q: How many 60-tablet packs should a distributor hold per patient per month? At 160mg twice daily a patient consumes four tablets daily, roughly two packs monthly. Build safety stock around that figure.

Q: Is a companion diagnostic mandatory before shipment to a hospital account? Reimbursement in most markets requires documented RET status, so hospitals generally pair orders with NGS or FISH testing capacity.